Examining the potential molecular mechanism, we found that CBX2 inhibits PTEN transcription by recruiting EZH2 to regulate the H3K27me3 level of the PTEN promoter and thus activates the AKT/mTOR pathway to accelerate glioma progression and TMZ chemoresistance. Here, AKT1 is linked to central nervous system cancer.